Beutel Goodman & Co Ltd. Raises Stock Position in Becton, Dickinson and Company $BDX

Key Points

• Beutel Goodman increased its Becton, Dickinson stake by 74.9% in the second quarter, bringing its holdings to 1.68 million shares worth approximately $254.9 million. Institutional investors collectively own 86.97% of the company.
• Becton, Dickinson reported quarterly earnings of $3.23 per share, exceeding estimates by $0.09, while revenue rose 5.4% year over year to $4.98 billion. The company maintained fiscal 2026 EPS guidance of $12.62–$12.72.
• The stock recently traded near its 52-week high at $191.95, while analysts maintained a consensus “Hold” rating with an average price target of $185.67. The company also announced a quarterly dividend of $1.05 per share, representing a 2.2% annualized yield.

Beutel Goodman & Co Ltd. boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 74.9% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 1,684,640 shares of the medical instruments supplier's stock after acquiring an additional 721,441 shares during the period. Becton, Dickinson and Company comprises about 1.9% of Beutel Goodman & Co Ltd.'s holdings, making the stock its 21st biggest holding. Beutel Goodman & Co Ltd. owned 0.61% of Becton, Dickinson and Company worth $254,936,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Brighton Jones LLC increased its stake in Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after buying an additional 877 shares in the last quarter. Empowered Funds LLC lifted its position in shares of Becton, Dickinson and Company by 20.4% in the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier's stock valued at $1,827,000 after acquiring an additional 1,354 shares in the last quarter. United Bank boosted its stake in Becton, Dickinson and Company by 23.9% during the 2nd quarter. United Bank now owns 5,149 shares of the medical instruments supplier's stock worth $887,000 after purchasing an additional 993 shares during the last quarter. Marshall Wace LLP grew its holdings in shares of Becton, Dickinson and Company by 365.1% during the second quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier's stock worth $5,491,000 after buying an additional 25,022 shares in the last quarter. Finally, NewEdge Advisors LLC raised its position in shares of Becton, Dickinson and Company by 34.7% in the second quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier's stock valued at $4,048,000 after buying an additional 6,058 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.

Insider Buying and Selling

In other news, EVP Roland Goette sold 2,438 shares of the business's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the transaction, the executive vice president directly owned 14,856 shares of the company's stock, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the company's stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the sale, the chief executive officer owned 110,163 shares in the company, valued at $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 11,779 shares of company stock valued at $1,974,669 in the last three months. 0.40% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $191.95 on Friday. The business has a 50-day moving average of $161.58 and a 200 day moving average of $161.13. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $192.30. The stock has a market capitalization of $52.89 billion, a price-to-earnings ratio of 57.82, a price-to-earnings-growth ratio of 13.53 and a beta of 0.19. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business's revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter last year, the firm posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company's payout ratio is presently 126.51%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on BDX shares. Evercore set a $180.00 price objective on shares of Becton, Dickinson and Company in a report on Monday, July 6th. Piper Sandler upped their price target on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Friday, August 7th. TD Cowen lifted their price objective on Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a "hold" rating in a research report on Wednesday, August 5th. Wells Fargo & Company raised their target price on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an "equal weight" rating in a research note on Friday, August 7th. Finally, UBS Group started coverage on Becton, Dickinson and Company in a report on Tuesday, July 28th. They set a "buy" rating and a $190.00 price target on the stock. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $185.67.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source